Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit

被引:77
|
作者
Croda, Julio [1 ,2 ]
Croda, Mariana Garcia
Neves, Alan [1 ]
dos Santos, Sigrid De Sousa [1 ]
机构
[1] Univ Sao Paulo, Infect & Parasit Dis Div, Lab Pathol Transmissible Dis, BR-05508 Sao Paulo, Brazil
[2] Univ Sao Paulo, Dept Pathol, Hosp Clin, Fac Med, BR-05508 Sao Paulo, Brazil
关键词
intensive care; human immunodeficiency virus; acquired immunodeficiency syndrome; antiretroviral therapy; prognostic factors; critical care; mortality; PNEUMOCYSTIS-CARINII-PNEUMONIA; HIV-INFECTION; PROGNOSTIC-FACTORS; PULMONARY COMPLICATIONS; HOSPITALIZED-PATIENTS; BACTERIAL PNEUMONIA; NATURAL-HISTORY; ICU SUPPORT; ERA; OUTCOMES;
D O I
10.1097/CCM.0b013e31819da8c7
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To evaluate the impact of antiretroviral therapy (ART) and the prognostic factors for in-intensive care unit (ICU) and 6-month mortality in human immunodeficiency virus (HIV)-infected patients. Design: A retrospective cohort study was conducted in patients admitted to the ICU from 1996 through 2006. The follow-up period extended for 6 months after ICU admission. Setting: The ICU of a tertiary-care teaching hospital at the Universidade de Sao Paulo, Brazil. Participants: A total of 278 HIV-infected patients admitted to the ICU were selected. We excluded ICU readmissions (37), ICU admissions who stayed less than 24 hours (44), and patients with unavailable medical charts (36). Outcome Measure: In-ICU and 6-month mortality. Main Results: Multivariate logistic regression analysis and Cox proportional hazards models demonstrated that the variables associated with in-ICU and 6-month mortality were sepsis as the cause of admission (odds ratio [OR] = 3.16 [95% confidence interval [CI] 1.65-6.06]); hazards ratio [HR] = 1.37 [95% Cl 1.01-1.88)), an Acute Physiology and Chronic Health Evaluation 11 score >19 [OR = 2.81 (95% CI 1.57-5.04); HR = 2.18 (95% CI 1.62-2.94)], mechanical ventilation during the first 24 hours [OR = 3.92 (95% CI 2.20-6.96); HR = 2.25 (95% CI 1.65-3.07)], and year of ICU admission [OR = 0.90 (95% CI 0.81-0.99); HR = 0.92 [95% CI 0.87-0.97)]. CD4 T-cell count <50 cells/mm(3) Was only associated with ICU mortality [OR = 2.10 (95% Cl 1.17-3.76)]. The use of ART in the ICU was negatively predictive of 6-month mortality in the Cox model [HR = 0.50 (95% CI 0.35-0.71)], especially if this therapy was introduced during the first 4 days of admission to the ICU [HR = 0.58 (95% CI 0.41-0.83)]. Regarding HIV-infected patients admitted to ICU without using ART, those who have started this treatment during ICU, stay presented a better prognosis when time and potential confounding factors were adjusted for [HR 0.55 (95% CI 0.31-0.98)]. Conclusions: The ICU outcome of HIV-infected patients seems to be dependent not only on acute illness severity, but also on the administration of antiretroviral treatment. (Crit Care Med 2009; 37: 1605-1611)
引用
收藏
页码:1605 / 1611
页数:7
相关论文
共 50 条
  • [21] Oral candidiasis in human immunodeficiency virus-infected patients under highly active antiretroviral therapy
    Shekatkar, Madhura
    Kheur, Supriya
    Gupta, Archana A.
    Arora, Aavishi
    Raj, A. Thirumal
    Patil, Shankargouda
    Khan, Samar Saeed
    Desai, Ami
    Carroll, William B.
    Awan, Kamran Habib
    DM DISEASE-A-MONTH, 2021, 67 (09):
  • [22] Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy
    Horberg, Michael A.
    Hurley, Leo B.
    Klein, Daniel B.
    Follansbee, Stephen E.
    Quesenberry, Charles
    Flamm, Jason A.
    Green, Gary M.
    Luu, Tye
    ARCHIVES OF SURGERY, 2006, 141 (12) : 1238 - 1245
  • [23] Proliferative Vitreoretinopathy in Human Immunodeficiency Virus-infected Patients in the Era of Highly Active Antiretroviral Therapy
    Kunavisarut, Paradee
    Bijlsma, Ward R.
    Pathanapitoon, Kessara
    Patikulsila, Direk
    Choovuthayakorn, Janejit
    Rothova, Aniki
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 150 (02) : 218 - 222
  • [24] SURVIVAL OF HIV-INFECTED PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT
    Adlakha, A. G.
    Pavlou, M.
    Walker, D.
    Copas, A. J.
    Batson, S.
    Edwards, S. G.
    Singer, M.
    Miller, R. F.
    THORAX, 2010, 65 : A38 - A39
  • [25] Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy
    Grimes, RM
    Otiniano, ME
    Rodriguez-Barradas, MC
    Lai, DJ
    CLINICAL INFECTIOUS DISEASES, 2002, 34 (11) : 1530 - 1533
  • [26] SURVIVAL OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS ON MAINTENANCE DIALYSIS
    FEINFELD, DA
    KAPLAN, R
    DRESSLER, R
    LYNN, RI
    CLINICAL NEPHROLOGY, 1989, 32 (05) : 221 - 224
  • [27] Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women -: In reply
    McGowan, JP
    Crane, M
    Wiznia, AA
    Blum, S
    OBSTETRICS AND GYNECOLOGY, 2000, 95 (04): : 636 - 637
  • [28] ANTIRETROVIRAL THERAPY AND MEDICAL-MANAGEMENT OF THE HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILD
    CONNOR, EM
    PIZZO, PA
    BALIS, F
    HUGHES, W
    KATZ, S
    MCSHERRY, G
    OLESKE, J
    SCOTT, G
    WARA, D
    WILFERT, C
    BURR, C
    GRUBMAN, S
    ABRAMS, E
    AMMANN, AJ
    BARDEGUEZ, A
    BALSLEY, JF
    BROADBENT, PA
    BROUWERS, P
    BRYSON, YJ
    COLLABELLI, N
    CONNOR, J
    COOPER, E
    DIAZ, C
    DIPAOLO, C
    FISCHER, GW
    FOWLER, MG
    FRENKEL, LM
    GRANT, R
    GOLDSMITH, JC
    GOOSBY, E
    GORDON, E
    HALE, AR
    HERNANDEZ, V
    HUSSON, R
    KOVACS, A
    KRASINSKI, K
    LUZURIAGA, K
    MCKINNEY, R
    MCINTOSH, K
    MCPHERSON, M
    MINTZ, M
    MOFENSON, LM
    MORETTI, L
    NYMAN, N
    OXTOBY, M
    RICHARTZ, K
    SANTACROSE, S
    SPECTOR, SA
    SPERLING, R
    TUDORWILLIAMS, G
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (06) : 513 - 522
  • [29] Immune therapy: Non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients
    Mitsuyasu, R
    JOURNAL OF INFECTIOUS DISEASES, 2002, 185 : S115 - S122
  • [30] Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy
    Wellons, MF
    Ottinger, JS
    Weinhold, KJ
    Gryszowka, V
    Sanders, LL
    Edwards, LJ
    Gooding, ME
    Thomasch, JR
    Bartlett, JA
    JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (10): : 1522 - 1525